These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11187397)

  • 1. Managing diabetes for improved health and economic outcomes.
    McCulloch D
    Am J Manag Care; 2000 Nov; 6(21 Suppl):S1089-95. PubMed ID: 11187397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic considerations in the management of type 2 diabetes.
    Clouse JC; Zitter M; Herman ME
    Manag Care Interface; 2002 Jan; 15(1):66-71. PubMed ID: 11828608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roundtable discussion. Glycemic control and economic issues.
    Basile F; McCulloch D; Brancati F
    Am J Manag Care; 2000 Nov; 6(21 Suppl):S1096-8. PubMed ID: 11187398
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential short-term economic benefits of improved glycemic control: a managed care perspective.
    Menzin J; Langley-Hawthorne C; Friedman M; Boulanger L; Cavanaugh R
    Diabetes Care; 2001 Jan; 24(1):51-5. PubMed ID: 11194241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatments for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD004730. PubMed ID: 33075159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC).
    Herman WH; Braffett BH; Kuo S; Lee JM; Brandle M; Jacobson AM; Prosser LA; Lachin JM
    J Diabetes Complications; 2018 Oct; 32(10):934-939. PubMed ID: 30064713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of postprandial glucose to treatments and outcomes in patients with type 2 diabetes.
    Herman ME; Moore RS
    Manag Care Interface; 2001 Nov; 14(11):63-9. PubMed ID: 11715766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
    Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
    J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring glycemic control: the cornerstone of diabetes care.
    LeRoith D; Smith DO
    Clin Ther; 2005 Oct; 27(10):1489-99. PubMed ID: 16330287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond.
    Fowler GC; Vasudevan DA
    South Med J; 2010 Sep; 103(9):911-6. PubMed ID: 20689486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system.
    Skyler JS
    Diabetes Technol Ther; 2000; 2 Suppl 1():S7-12. PubMed ID: 11469636
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(20):1-58. PubMed ID: 23074525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic Pentad.
    Forum GP
    J Assoc Physicians India; 2017 Jul; 65(7):68-79. PubMed ID: 28792171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
    Salas M; Ward A; Caro J
    Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved glycemic control results in short-term cost savings, researchers find.
    Lieder TR
    Am J Health Syst Pharm; 2001 Mar; 58(5):373. PubMed ID: 11258170
    [No Abstract]   [Full Text] [Related]  

  • 19. A cost effectiveness study of integrated care in health services delivery: a diabetes program in Australia.
    McRae IS; Butler JR; Sibthorpe BM; Ruscoe W; Snow J; Rubiano D; Gardner KL
    BMC Health Serv Res; 2008 Oct; 8():205. PubMed ID: 18834551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE).
    Newman SP; Cooke D; Casbard A; Walker S; Meredith S; Nunn A; Steed L; Manca A; Sculpher M; Barnard M; Kerr D; Weaver J; Ahlquist J; Hurel SJ
    Health Technol Assess; 2009 May; 13(28):iii-iv, ix-xi, 1-194. PubMed ID: 19476724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.